Forte Biosciences, Inc. FBRX
Institutional shares held
174,858
0
calls
0
puts
Total value of holdings
$1.02M
$0
calls
$0
puts
Market Cap
$119M
20,340,300
Shares Out.
Institutional ownership
0.86%
# of Institutions
1
We take great care to ensure that the data presented and summarized in this overview for Forte Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FBRX
View allLatest Institutional Activity in FBRX
Top Purchases
Top Sells
About FBRX
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Insider Transactions at FBRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
133
-1.58%
|
$665
$5.16 P/Share
|
|
Oct 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
375
+4.28%
|
-
|
|
Oct 01
2024
|
Paul A. Wagner |
SELL
Payment of exercise price or tax liability
|
Direct |
98
-0.13%
|
$490
$5.16 P/Share
|
|
Oct 01
2024
|
Paul A. Wagner |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.59%
|
-
|
|
Jul 01
2024
|
Paul A. Wagner |
SELL
Payment of exercise price or tax liability
|
Direct |
2,453
-0.13%
|
$0
$0.55 P/Share
|
|
Jul 01
2024
|
Paul A. Wagner |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+1.61%
|
-
|
|
Jul 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,345
-1.64%
|
$0
$0.55 P/Share
|
|
Jul 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+4.4%
|
-
|
|
Apr 01
2024
|
Paul A. Wagner |
SELL
Payment of exercise price or tax liability
|
Direct |
2,453
-0.13%
|
$0
$0.71 P/Share
|
|
Apr 01
2024
|
Paul A. Wagner |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+1.63%
|
-
|
|
Apr 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,345
-1.69%
|
$0
$0.71 P/Share
|
|
Apr 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+4.52%
|
-
|
|
Jan 01
2024
|
Paul A. Wagner |
SELL
Payment of exercise price or tax liability
|
Direct |
4,109
-0.22%
|
$0
$0.82 P/Share
|
|
Jan 01
2024
|
Paul A. Wagner |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+1.66%
|
-
|
|
Jan 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,841
-2.0%
|
$0
$0.82 P/Share
|
|
Jan 01
2024
|
Antony A Riley CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+4.65%
|
-
|
|
Jan 01
2024
|
Hubert C Chen Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,073
-3.19%
|
$0
$0.82 P/Share
|
|
Jan 01
2024
|
Hubert C Chen Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+7.21%
|
-
|
|
Dec 18
2023
|
Paul A. Wagner |
BUY
Open market or private purchase
|
Direct |
10,000
+0.55%
|
$0
$0.75 P/Share
|
|
Dec 14
2023
|
Paul A. Wagner |
BUY
Open market or private purchase
|
Direct |
10,000
+0.55%
|
$0
$0.72 P/Share
|
Last 12 Months Summary
Buy / Acquisition
250K
Shares
From
4
Insiders
| Exercise of conversion of derivative security | 131K shares |
|---|---|
| Open market or private purchase | 119K shares |
Sell / Disposition
22.9K
Shares
From
3
Insiders
| Payment of exercise price or tax liability | 22.9K shares |
|---|